Evidence map›Paper›PMID 40766110›Full record

ArticleFrontiers in nephrology2022

Corrigendum: Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients.

T Van Meerhaeghe, J F Baurain, O Bechter, C Orte Cano, V Del Marmol, A Devresse, P Doubel, M Hanssens, R Hellemans, D Lienard and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

T Van MeerhaegheDepartment of Nephrology, Hôpital Erasme - Université Libre de Bruxelles (ULB), Brussels, Belgium.
J F BaurainDepartment of Oncology, Clinique Universitaire Saint-Luc - Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
O BechterDepartment of Oncology, Universitair Ziekenhuis (UZ) Leuven - Katholieke Universiteit Leuven (KUL), Leuven, Belgium.
C Orte CanoDepartment of Dermatology, Hôpital Erasme - Université Libre de Bruxelles (ULB), Brussels, Belgium.
V Del MarmolDepartment of Dermatology, Hôpital Erasme - Université Libre de Bruxelles (ULB), Brussels, Belgium.
A DevresseDepartment of Nephrology, Clinique Universitaire Saint-Luc - Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
P DoubelDepartment of Nephrology, Academisch Ziekenhuis (AZ) Groeninge, Kortrijk, Belgium.
M HanssensDepartment of Oncology, Academisch Ziekenhuis (AZ) Groeninge, Kortrijk, Belgium.
R HellemansDepartement of Nephrology, Universitair Ziekenhuis (UZ) Antwerpen, Antwerpen, Belgium.
D LienardDepartment of Dermatology, Hôpital Erasme - Université Libre de Bruxelles (ULB), Brussels, Belgium.
A RuttenDepartment of Oncology, GasthuisZuster, Antwerpen, Belgium.
B SprangersDepartment of Nephrology, Universitair Ziekenhuis (UZ) Leuven - Katholieke Universiteit Leuven (KUL), Leuven, Belgium.
A Le MoineDepartment of Nephrology, Hôpital Erasme - Université Libre de Bruxelles (ULB), Brussels, Belgium.
S AspeslaghDepartment of Oncology, Universitair Ziekenhuis (UZ) Brussel - Vrije Universiteit Brussel (VUB), Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fneph.2022.1041819.].

Indexed as

cemiplimabcutaneous squamous cell carcinomaimmune checkpoint inhibitorskidney transplant recipientsrejection

Identifiers

PMID40766110
PMCPMC12322978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.